FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308001978> ?p ?o ?g. }

• W4308001978 abstract "Non-infectious intermediate, posterior, and panuveitis (NIIPPU) represent a heterogenous collection of autoimmune and inflammatory disorders isolated to or concentrated in the posterior structures of the eye. Because NIIPPU is typically a chronic condition, people with NIIPPU frequently require treatment with steroid-sparing immunosuppressive therapy. Methotrexate, mycophenolate, cyclosporine, azathioprine, and tacrolimus are non-biologic, disease-modifying antirheumatic drugs (DMARDs) which have been used to treat people with NIIPPU.To compare the effectiveness and safety of selected DMARDs (methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and azathioprine) in the treatment of NIIPPU in adults.We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register), MEDLINE, Embase, the Latin American and Caribbean Health Sciences database, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform, most recently on 16 April 2021.We included randomized controlled trials (RCTs) comparing selected DMARDs (methotrexate, mycophenolate, tacrolimus, cyclosporine, and azathioprine) with placebo, standard of care (topical steroids, with or without oral steroids), or with each other.We used standard methodological procedures expected by Cochrane.We included 11 RCTs with a total of 601 participants in this review. DMARDs versus control Two studies compared an experimental DMARD (cyclosporine A or enteric-coated mycophenolate [EC-MPS]) plus oral steroid with steroid monotherapy. We did not pool these results into a meta-analysis because the dose of cyclosporine used was much higher than that used in current clinical practice. The evidence is very uncertain about whether EC-MPS plus low-dose oral steroid results in a higher proportion of participants achieving control of inflammation over steroid monotherapy (risk ratio [RR] 2.81, 95% confidence interval [CI] 1.10 to 7.17; 1 study, 41 participants; very low-certainty evidence). The change in best-corrected visual acuity (BCVA) was reported separately for right and left eyes. The evidence for improvement (lower logarithm of the minimum angle of resolution (logMAR) indicates better vision) between the groups is very uncertain (mean difference [MD] -0.03 and -0.10, 95% CI -0.96 to 0.90 and -0.27 to 0.07 for right and left, respectively; 1 study, 82 eyes; very low-certainty evidence). No data were available for the following outcomes: proportion of participants achieving a 2-line improvement in visual acuity, with confirmed macular edema, or achieving steroid-sparing control. The evidence for the proportion of participants requiring cessation of medication in the DMARD versus control group is very uncertain (RR 2.61, 95% CI 0.11 to 60.51; 1 study, 41 participants; very low-certainty evidence). Methotrexate versus mycophenolate We were able to combine two studies into a meta-analysis comparing methotrexate versus mycophenolate mofetil. Methotrexate probably results in a slight increase in the proportion of participants achieving control of inflammation, including steroid-sparing control, compared to mycophenolate at six months (RR 1.23, 95% CI 1.01 to 1.50; 2 studies, 261 participants; moderate-certainty evidence). Change in BCVA was reported per eye and the treatments likely result in little to no difference in change in vision (MD 0.01 logMAR higher [worse] for methotrexate versus mycophenolate; 2 studies, 490 eyes; moderate-certainty evidence). No data were available for the proportion of participants achieving a 2-line improvement in visual acuity. The evidence is very uncertain regarding the proportion of participants with confirmed macular edema between methotrexate versus mycophenolate (RR 0.49, 95% CI 0.19 to 1.30; 2 studies, 35 eyes; very low-certainty). Methotrexate versus mycophenolate may result in little to no difference in the proportion of participants requiring cessation of medication (RR 0.99, 95% CI 0.43 to 2.27; 2 studies, 296 participants; low-certainty evidence). Steroids with or without azathioprine versus cyclosporine A Four studies compared steroids with or without azathioprine (oral steroids, intravenous [IV] steroids, or azathioprine) to cyclosporine A. We excluded two studies from the meta-analysis because the participants were treated with 8 mg to 15 mg/kg/day of cyclosporine A, a significantly higher dose than is utilized today because of concerns for nephrotoxicity. The remaining two studies were conducted in all Vogt-Koyanagi-Harada disease (VKH) populations and compared cyclosporine A to azathioprine or IV pulse-dose steroids. The evidence is very uncertain for whether the steroids with or without azathioprine or cyclosporine A influenced the proportion of participants achieving control of inflammation (RR 0.84, 95% CI 0.70 to 1.02; 2 studies, 112 participants; very low-certainty evidence), achieving steroid-sparing control (RR 0.64, 95% CI 0.33 to 1.25; 1 study, 21 participants; very low-certainty evidence), or requiring cessation of medication (RR 0.85, 95% 0.21 to 3.45; 2 studies, 91 participants; very low-certainty evidence). The evidence is uncertain for improvement in BCVA (MD 0.04 logMAR lower [better] with the steroids with or without azathioprine versus cyclosporine A; 2 studies, 91 eyes; very low-certainty evidence). There were no data available (with current cyclosporine A dosing) for the proportion of participants achieving a 2-line improvement in visual acuity or with confirmed macular edema. Studies not included in synthesis We were unable to include three studies in any of the comparisons (in addition to the aforementioned studies excluded based on historic doses of cyclosporine A). One was a dose-response study comparing cyclosporine A to cyclosporine G, a formulation which was never licensed and is not clinically available. We excluded another study from meta-analysis because it compared cyclosporine A and tacrolimus, considered to be of the same class (calcineurin inhibitors). We were unable to combine the third study, which examined tacrolimus monotherapy versus tacrolimus plus oral steroid, with any group.There is a paucity of data regarding which DMARD is most effective or safe in NIIPPU. Studies in general were small, heterogenous in terms of their design and outcome measures, and often did not compare different classes of DMARD with each other. Methotrexate is probably slightly more efficacious than mycophenolate in achieving control of inflammation, including steroid-sparing control (moderate-certainty evidence), although there was insufficient evidence to prefer one medication over the other in the VKH subgroup (very low-certainty evidence). Methotrexate may result in little to no difference in safety outcomes compared to mycophenolate." @default.
• W4308001978 created "2022-11-07" @default.
• W4308001978 creator A5007725602 @default.
• W4308001978 creator A5009403765 @default.
• W4308001978 creator A5022308888 @default.
• W4308001978 creator A5022755706 @default.
• W4308001978 creator A5072760500 @default.
• W4308001978 creator A5076652612 @default.
• W4308001978 date "2022-10-31" @default.
• W4308001978 modified "2023-10-17" @default.
• W4308001978 title "Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults" @default.
• W4308001978 cites W1966421860 @default.
• W4308001978 cites W1970617962 @default.
• W4308001978 cites W1973387000 @default.
• W4308001978 cites W1975065988 @default.
• W4308001978 cites W1979496435 @default.
• W4308001978 cites W1996434265 @default.
• W4308001978 cites W1997972850 @default.
• W4308001978 cites W2008597795 @default.
• W4308001978 cites W2014402123 @default.
• W4308001978 cites W2032193530 @default.
• W4308001978 cites W2036941085 @default.
• W4308001978 cites W2043198160 @default.
• W4308001978 cites W2047901258 @default.
• W4308001978 cites W2061663565 @default.
• W4308001978 cites W2065541718 @default.
• W4308001978 cites W2075332893 @default.
• W4308001978 cites W2078531117 @default.
• W4308001978 cites W2088625402 @default.
• W4308001978 cites W2093944124 @default.
• W4308001978 cites W2096060458 @default.
• W4308001978 cites W2111615368 @default.
• W4308001978 cites W2115797323 @default.
• W4308001978 cites W2122888527 @default.
• W4308001978 cites W2134048257 @default.
• W4308001978 cites W2139499737 @default.
• W4308001978 cites W2148298419 @default.
• W4308001978 cites W2152113638 @default.
• W4308001978 cites W2170347817 @default.
• W4308001978 cites W2321199594 @default.
• W4308001978 cites W2417836626 @default.
• W4308001978 cites W2418720791 @default.
• W4308001978 cites W2419516812 @default.
• W4308001978 cites W2490505209 @default.
• W4308001978 cites W2534801358 @default.
• W4308001978 cites W2560086159 @default.
• W4308001978 cites W2562032385 @default.
• W4308001978 cites W2605656853 @default.
• W4308001978 cites W2607125258 @default.
• W4308001978 cites W2754698852 @default.
• W4308001978 cites W2782470740 @default.
• W4308001978 cites W2945866604 @default.
• W4308001978 cites W2972552619 @default.
• W4308001978 cites W2973195897 @default.
• W4308001978 cites W3026395387 @default.
• W4308001978 cites W3027167654 @default.
• W4308001978 cites W3048908572 @default.
• W4308001978 cites W3081702912 @default.
• W4308001978 cites W3125261197 @default.
• W4308001978 cites W3134853783 @default.
• W4308001978 cites W3136868194 @default.
• W4308001978 cites W3211291193 @default.
• W4308001978 cites W4214624495 @default.
• W4308001978 cites W421642 @default.
• W4308001978 cites W4246758803 @default.
• W4308001978 cites W4256489446 @default.
• W4308001978 cites W4308001978 @default.
• W4308001978 cites W1551752963 @default.
• W4308001978 doi "https://doi.org/10.1002/14651858.cd014831.pub2" @default.
• W4308001978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36315029" @default.
• W4308001978 hasPublicationYear "2022" @default.
• W4308001978 type Work @default.
• W4308001978 citedByCount "2" @default.
• W4308001978 countsByYear W43080019782022 @default.
• W4308001978 countsByYear W43080019782023 @default.
• W4308001978 crossrefType "journal-article" @default.
• W4308001978 hasAuthorship W4308001978A5007725602 @default.
• W4308001978 hasAuthorship W4308001978A5009403765 @default.
• W4308001978 hasAuthorship W4308001978A5022308888 @default.
• W4308001978 hasAuthorship W4308001978A5022755706 @default.
• W4308001978 hasAuthorship W4308001978A5072760500 @default.
• W4308001978 hasAuthorship W4308001978A5076652612 @default.
• W4308001978 hasConcept C126322002 @default.
• W4308001978 hasConcept C142724271 @default.
• W4308001978 hasConcept C168563851 @default.
• W4308001978 hasConcept C197934379 @default.
• W4308001978 hasConcept C204787440 @default.
• W4308001978 hasConcept C27081682 @default.
• W4308001978 hasConcept C2776760755 @default.
• W4308001978 hasConcept C2778033501 @default.
• W4308001978 hasConcept C2779134260 @default.
• W4308001978 hasConcept C2781059491 @default.
• W4308001978 hasConcept C2909675724 @default.
• W4308001978 hasConcept C2911091166 @default.
• W4308001978 hasConcept C535046627 @default.
• W4308001978 hasConcept C71924100 @default.
• W4308001978 hasConceptScore W4308001978C126322002 @default.
• W4308001978 hasConceptScore W4308001978C142724271 @default.
• W4308001978 hasConceptScore W4308001978C168563851 @default.
• W4308001978 hasConceptScore W4308001978C197934379 @default.

• next